PT-141 for Women: What You Need to Know About Bremelanotide and Low Libido

If you have been searching for answers about low libido, you have probably come across PT-141. It comes up in conversations about women's health, peptide therapy, and sexual wellness in ways that feel both promising and confusing. What actually is it? Does the research support it? And what would it mean for you specifically?

This article covers what PT-141 (bremelanotide) is, how it works in the body, what the clinical trials show in women, and what you need to know about dosing, side effects, and your options. It is not medical advice, and any treatment decision should be made with a licensed healthcare provider who knows your history.

*This article is for educational purposes only. It is not medical advice. Always consult a licensed healthcare provider before starting any treatment. Vyleesi (bremelanotide) is FDA-approved for HSDD in premenopausal women. Compounded bremelanotide is not FDA-approved and is not the same as, equivalent to, or interchangeable with Vyleesi.*

---

What PT-141 Actually Is

PT-141 is the research name for bremelanotide, a synthetic peptide originally developed as a melanocyte-stimulating hormone analog. It was first studied as a potential tanning agent, but early trials turned up an unexpected side effect: increased sexual arousal. That discovery redirected the compound's entire development trajectory.

After more than a decade of clinical testing, bremelanotide received FDA approval in June 2019 under the brand name Vyleesi. The approved indication is hypoactive sexual desire disorder (HSDD) in premenopausal women.

PT-141 is not a hormone. It is not sildenafil or any other phosphodiesterase inhibitor. It works through a completely different system than any prior treatment for sexual dysfunction, which is one reason it has drawn significant research interest.

---

Why "Low Libido" Is Often Something More Specific

Many women experience periods of reduced sexual interest. That alone is not a disorder. What distinguishes HSDD is the combination of persistently low desire and personal distress caused by that low desire.

Research suggests that meaningful distress about low sexual desire affects roughly 8 to 10 percent of U.S. women (West SL et al., Archives of Internal Medicine, PMID: 18625925). The proportion is higher among perimenopausal and postmenopausal women, but HSDD also occurs in premenopausal women at every life stage.

The causes are usually multiple. Hormonal shifts (especially declining testosterone, which plays a role in female desire), stress, relationship dynamics, sleep quality, certain medications (including oral contraceptives and antidepressants), and underlying health conditions can all contribute. HSDD is not simply the absence of interest. It is the distress that absence causes.

If you feel like your low libido is affecting your quality of life, your relationship, or your sense of self, that experience is clinically meaningful and worth discussing with a provider.

---

How PT-141 Works: The Brain, Not the Body

What makes PT-141 distinct from every other treatment in this space is its mechanism. Most medications for sexual dysfunction act on the body's vascular or hormonal systems. PT-141 acts on the brain.

Bremelanotide is a melanocortin receptor agonist. It activates MC4R (melanocortin 4 receptor) and MC3R, which are expressed in central nervous system regions involved in sexual motivation, reward, and arousal.

A 2022 study published in the Journal of Clinical Investigation demonstrated this central effect directly. Thurston and colleagues found that MC4R agonism enhanced processing of sexual stimuli in brain regions associated with arousal in women with HSDD (Thurston L et al., PMID: 36189794). This provides mechanistic evidence that PT-141 works at the level of desire circuitry, not peripheral blood flow.

This matters because desire is neurological before it is physical. If your challenge is low motivation for sexual activity rather than difficulty with physical arousal, a centrally acting compound addresses the problem at its source.

---

What the Clinical Trials Found in Women

The most important data on PT-141 for women comes from the RECONNECT trials, two Phase 3 randomized, double-blind, placebo-controlled studies that enrolled 1,267 premenopausal women with HSDD.

Published in Obstetrics and Gynecology in November 2019 (Kingsberg SA et al., PMID: 31599840), the RECONNECT results showed:

• Women taking bremelanotide had statistically significant increases in sexual desire compared to placebo (Study 301: p less than 0.001; Study 302: p less than 0.001)
• Women taking bremelanotide had statistically significant reductions in distress related to low sexual desire compared to placebo
• Side effects including nausea, flushing, and headache occurred in 10 percent or more of participants in both studies
• Most adverse events were mild to moderate in severity

A Phase 2b dose-finding trial that preceded RECONNECT, published in Women's Health in 2016 (Clayton AH et al., PMID: 27181790), established the 1.75 mg dose used in the Phase 3 program and demonstrated early efficacy signals.

The long-term extension of RECONNECT, published alongside the primary paper (Simon JA et al., PMID: 31599847), followed women who completed the 24-week trial into a 52-week open-label extension. The safety profile remained consistent with the core phase, and the efficacy benefits were maintained over the longer observation period.

Subgroup analyses published in the Journal of Women's Health (Simon JA et al., PMID: 35230162) examined outcomes across different demographic groups within the RECONNECT population and found consistent benefit patterns.

What the Numbers Mean in Practice

The outcome measures in RECONNECT were the Female Sexual Function Index desire domain and the Female Sexual Distress Scale-DAO (item 13, which captures distress about low desire). Both are validated, patient-reported tools.

The improvements were statistically significant, meaning they were not explained by chance. Whether they were meaningful in the way that matters to you in your life is a separate question, one worth discussing with a provider who can review the actual effect sizes in context.

---

*Making an informed decision about sexual health treatment starts with understanding the research.*

---

Dosing and How It Is Used

The FDA-approved form, Vyleesi, is administered as a 1.75 mg subcutaneous injection approximately 45 minutes before anticipated sexual activity. It is designed for on-demand use rather than daily dosing, which is one difference from flibanserin (Addyi), the other FDA-approved HSDD treatment.

The on-demand nature appeals to some women because it does not require taking a daily medication. Others find a daily pill more predictable. Neither is objectively better. They reflect different preferences and different mechanisms.

The 45-minute onset window is important to understand before considering this approach. Spontaneity in the way many people think about it is not how this medication works. It requires some planning.

---

Side Effects to Know

Nausea is the most common side effect. In the RECONNECT trials, nausea, flushing, and headache each occurred in at least 10 percent of participants. Nausea was the most reported adverse event and led some participants to discontinue.

Strategies used in the trials to manage nausea included injection site selection and timing. Providers sometimes recommend antiemetics for patients who experience significant nausea.

Bremelanotide can also cause a transient increase in blood pressure following administration. Blood pressure generally returns to baseline within 12 hours. This makes the medication unsuitable for women with uncontrolled hypertension or significant cardiovascular disease. Your provider will assess whether this is a concern for you.

The full list of warnings and contraindications is available in the Vyleesi prescribing information and should be reviewed with your provider.

---

Vyleesi vs. Compounded PT-141: An Important Distinction

This is one of the most important clarifications to make clearly.

Vyleesi is the FDA-approved drug. It contains bremelanotide at 1.75 mg per dose in a standardized auto-injector. Its safety and efficacy have been established through the clinical trial program described above.

Compounded bremelanotide is not FDA-approved. It is not the same as Vyleesi, has not gone through the same regulatory review, and may differ in formulation, concentration, delivery method, or sterility standards. Compounded versions are not approved to treat any condition and are not interchangeable with the FDA-approved product.

Any provider prescribing or recommending compounded bremelanotide should be discussing that distinction with you explicitly. The decision to use a compounded product involves accepting that the evidence base comes from the FDA-approved formulation, not the compounded version.

Licensed providers in our affiliated network are available to evaluate your individual situation, review your health history, and discuss whether any treatment options are appropriate for you. They can help you understand the difference between FDA-approved and compounded options in your specific case.

---

Who the Research Enrolled and Who It Did Not

The RECONNECT trials enrolled premenopausal women with a formal HSDD diagnosis and meaningful distress. Understanding who was and was not studied matters for interpreting whether the research applies to your situation.

Bremelanotide has not been studied or approved for postmenopausal women, men, or people whose low desire is primarily driven by relationship or situational factors rather than a consistent physiological pattern.

The trials also excluded women with active cardiovascular disease, uncontrolled hypertension, and certain other medical conditions. These are exclusion criteria that a provider will assess as part of determining whether any treatment is appropriate for you.

---

How PT-141 Compares to Flibanserin (Addyi)

Both PT-141 (bremelanotide) and flibanserin (Addyi) are FDA-approved for HSDD in premenopausal women. They work differently and have different practical profiles.

Flibanserin is a daily oral tablet that acts on serotonin and dopamine receptors. It requires consistent daily use, takes weeks to show effect, and carries a serious alcohol interaction that prompted an FDA-mandated risk evaluation and mitigation strategy (REMS). It does not work on an as-needed basis.

Bremelanotide is an as-needed injectable that works through melanocortin receptors. It takes effect within 45 minutes and does not have the same alcohol interaction profile as flibanserin.

For some women, a daily oral medication fits their routine better. For others, the on-demand nature of bremelanotide is more practical. Some providers have used both in sequence when one is not effective or tolerated. This is a conversation worth having with a provider rather than a decision to make on your own.

---

Frequently Asked Questions

Is PT-141 the same as Vyleesi? Bremelanotide is the active compound in both. Vyleesi is the FDA-approved product. Compounded PT-141 contains the same compound but is not FDA-approved.

Will it work if my low libido is related to stress or relationship issues? The RECONNECT trials enrolled women with HSDD as a physiological pattern, not primarily situational low desire. If the driver is largely situational or relational, pharmacological approaches may not address the root cause. A provider can help assess this distinction.

How quickly does it take effect? The approved form is designed for use approximately 45 minutes before sexual activity. This is not an immediate effect.

Does it cause nausea in everyone? No. Nausea occurred in a meaningful proportion of trial participants but not all. Severity varied, and for many it was mild or manageable.

Is this related to Melanotan? PT-141 and Melanotan II are both melanocortin analogs derived from the same research lineage, but they are distinct compounds with different regulatory histories. Melanotan II is not FDA-approved for any indication.

---

The Bigger Picture

If you are experiencing distress about low sexual desire, you are not alone and the conversation is worth having with a provider. The research base for bremelanotide in premenopausal women with HSDD is among the strongest for any approved treatment in this area, with two Phase 3 trials and a long-term extension study.

Whether it is the right approach for you depends on your health history, your preferences, and a conversation with a licensed provider.

For more context on how PT-141 fits into the broader landscape of sexual health research, see the article on [PT-141 (Bremelanotide): What the Research Says](/resources/pt-141-bremelanotide-sexual-health-research). For an overview of all evidence-backed treatment options for female sexual dysfunction, see the [Female Sexual Dysfunction Treatment Options guide](/resources/female-sexual-dysfunction-treatment-options-2026).

*This article is for educational purposes only and does not constitute medical advice. Vyleesi (bremelanotide) is FDA-approved for the treatment of HSDD in premenopausal women. Compounded bremelanotide is not FDA-approved and is not equivalent to or interchangeable with Vyleesi. Individual results vary. Consult your licensed healthcare provider before starting any treatment. Prescriva is a Management Services Organization that provides administrative support to affiliated licensed providers. Treatment decisions are made by licensed providers in our affiliated network, not by Prescriva. This content refers to clinical trial data from FDA-approved formulations; compounded products have not been evaluated by the FDA for safety or efficacy. Vyleesi is a registered trademark of Palatin Technologies, Inc. Prescriva is not affiliated with, endorsed by, or sponsored by Palatin Technologies.*

---

Sources

1. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. *Obstetrics and Gynecology.* 2019;134(5):899-908. [PMID: 31599840](https://pubmed.ncbi.nlm.nih.gov/31599840/)

1. Simon JA, Kingsberg SA, Portman D, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. *Obstetrics and Gynecology.* 2019;134(5):909-917. [PMID: 31599847](https://pubmed.ncbi.nlm.nih.gov/31599847/)

1. Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. *Women's Health (London, England).* 2016. [PMID: 27181790](https://pubmed.ncbi.nlm.nih.gov/27181790/)

1. Simon JA, Kingsberg SA, Portman D, et al. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. *Journal of Women's Health.* 2022. [PMID: 35230162](https://pubmed.ncbi.nlm.nih.gov/35230162/)

1. Thurston L, Hunjan T, Mills EG, et al. Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder. *The Journal of Clinical Investigation.* 2022. [PMID: 36189794](https://pubmed.ncbi.nlm.nih.gov/36189794/)

1. West SL, D'Aloisio AA, Agans RP, et al. Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women. *Archives of Internal Medicine.* 2008. [PMID: 18625925](https://pubmed.ncbi.nlm.nih.gov/18625925/)

---

Talk With a Provider

If this sounds like it might be relevant to you, the next step is a conversation with a licensed healthcare provider. Prescriva connects you with licensed providers in our affiliated network who can evaluate your individual situation, review your history, and discuss whether any treatment options, including those for HSDD, may be appropriate.

*Consult your healthcare provider. Individual results vary. This is not medical advice.*

[Connect With a Provider](#)